Kapoor Shailendra
Shailendra Kapoor, Private practice, 7487 Sherwood Crossing place # 302, Mechanicsville, VA 23111, United States.
World J Clin Oncol. 2012 Aug 10;3(8):126-7. doi: 10.5306/wjco.v3.i8.126.
I read with great interest the recent article by Cordero et al in a recent issue of your esteemed journal. Interestingly, the past few years have seen the emergence of CD26 as an important diagnostic and prognostic marker for a number of systemic malignancies besides colo-rectal carcinomas. For instance, serum CD26 levels are an important emerging marker of B-cell chronic lymphocytic leukemia (B-CLL). In fact, Molica et al have recently reported shorter time to first treatment in B-CLL which exhibit higher serum CD26 levels and simultaneously demonstrate absence of mutation in IgV (H). Similarly, CD26 serves as a marker of poor prognosis in T cell lymphomas. Simultaneously, a poor response to 2'-deoxycoformycin is seen T cell lymphomas expressing CD26. Similarly, breast carcinomas exhibit decreased CD26 mean fluorescence intensity and a decreased percentage of CD26 positive lymphocytes in comparison to benign breast tumors and healthy individuals.
我饶有兴趣地拜读了科尔德罗等人近期发表在贵刊上的文章。有趣的是，在过去几年里，除了结直肠癌外，CD26已成为多种系统性恶性肿瘤的重要诊断和预后标志物。例如，血清CD26水平是B细胞慢性淋巴细胞白血病（B-CLL）一个重要的新兴标志物。事实上，莫利卡等人最近报告称，在血清CD26水平较高且同时显示IgV（H）无突变的B-CLL患者中，首次治疗时间较短。同样，CD26是T细胞淋巴瘤预后不良的标志物。同时，在表达CD26的T细胞淋巴瘤中，对2'-脱氧助间型霉素的反应较差。同样，与良性乳腺肿瘤和健康个体相比，乳腺癌患者的CD26平均荧光强度降低，CD26阳性淋巴细胞百分比降低。
